Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)

Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)

Efficacy and safety of tiotropium+olodaterol fixed-dose combination (FDC) compared with the mono-components was evaluated in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) in two replicate, randomised, double-blind, parallel-group, multicentre, phase III trials.

Bibliographic Details
Main Authors: Buhl, Roland, Maltais, François, Abrahams, Roger, Bjermer, Leif, Derom, Eric, Ferguson, Gary, Fležar, Matjaž, Hébert, Jacques, McGarvey, Lorcan, Pizzichini, Emilio, Reid, Jim, Veale, Antony, Grönke, Lars, Hamilton, Alan, Korducki, Lawrence, Tetzlaff, Kay, Waitere-Wijker, Stella, Watz, Henrik, Bateman, Eric
Format: Online
Language:English
Published: European Respiratory Society 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4391658/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4391658/

Similar Items